B. Riley Financial Varied
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Elanco Animal Health Incorporated Common Stock (NY: ELAN )

11.88 +0.02 (+0.17%)
Official Closing Price Updated: 5:00 PM EST, Dec 24, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Elanco Animal Health Incorporated Common Stock

< Previous 1 2 3 4 5 6 Next >
Big Biopharma Trails Behind The Market: JP Morgan's 2025 Outlook on Eli Lilly, Merck, and More
JP Morgan highlights 2025 growth prospects for biopharma, animal health, and specialty pharma stocks. Key picks include Eli Lilly, Zoetis, and Bristol-Myers Squibb. 
Via Benzinga
This Six Flags Entertainment Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
Via Benzinga
Top 3 Health Care Stocks That Could Blast Off In December
Via Benzinga
Analyst Ratings For Elanco Animal Health
Via Benzinga
Elanco Animal Health (ELAN) Q3 2024 Earnings Call Transcript
ELAN earnings call for the period ending September 30, 2024. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Evaluating Elanco Animal Health: Insights From 4 Financial Analysts
Via Benzinga
Demystifying Elanco Animal Health: Insights From 4 Analyst Reviews
Via Benzinga
A Closer Look at 4 Analyst Recommendations For Elanco Animal Health
Via Benzinga
Elanco Animal Q3 Earnings: Profit Beat, New Products And Stabilized Business To Drive 2025 Sales
Elanco Animal Health reports Q3 revenue of $1.03 billion, with a 4% decline and adjusted EPS of $0.13, beating estimates. Guidance tightened for 2024 sales and EPS. 
Via Benzinga
Elanco's Dermatology Treatment Secures FDA Approval For Itchy Dogs, Analyst Highlights Label Warnings And Efficacy
FDA approves Elanco's once-daily oral treatment, Zenrelia, for controlling itching in dogs with allergic and atopic dermatitis. The drug, proven effective in studies, faces adoption challenges due to... 
Via Benzinga
Exposures Product Safety
Robinhood To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Thursday
Via Benzinga
Loar Holdings Posts Upbeat Results, Joins Nvidia, Clean Energy Fuels, Penumbra And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
The Latest Analyst Ratings For Elanco Animal Health
Via Benzinga
Breaking Down Elanco Animal Health: 6 Analysts Share Their Views
Via Benzinga
Elanco Animal Health (ELAN) Q2 2024 Earnings Call Transcript
ELAN earnings call for the period ending June 30, 2024. 
Via The Motley Fool
Topics Earnings
Exposures Financial
7 Healthcare Stocks to Buy for Positive Inflation-Adjusted Returns
These are the healthcare stocks to buy as they represent companies with good fundamentals, stable growth visibility and cash flow upside. 
Via InvestorPlace
Merk Animal Health Completes Acquisition of Elanco Animal Health Assets
Merck Animal Health announced the purchase of Elanco Animal Health's aquaculture business.Merck & Company (NYSE:MRK) completed the acquisition of the aquaculture bus 
Via Benzinga
Citigroup, Elanco Animal Health And A Tech Stock: CNBC's 'Final Trades'
Analysts expect Citigroup to report good earnings on Friday. Stephanie Link chose Elanco for its new products. Corning increased its sales guidance. 
Via Benzinga
Elanco Animal Health Shares Sink On Unexpected Label Update For Canine Dermatology Drug
Elanco Animal Health shares drop after updates on FDA approval timelines for Zenrelia and Credelio Quattro. Zenrelia's U.S. label includes a boxed warning, impacting adoption. U.S. launches for both... 
Via Benzinga
Exposures Product Safety
Fluffy's Drugmaker Elanco Animal Health Plummets On Unexpected Safety Warning
The company is working on treatments for eczema and parasite prevention. 
Via Investor's Business Daily
Levi Strauss Posts Mixed Results, Joins Walgreens, AeroVironment And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Via Benzinga
Bargain Bin: 3 Cheap Stocks to Buy Before Memorial Day
Summer has arrived on Wall Street! Discover three cheap stocks to buy with solid fundamentals to boost your profitability this season. 
Via InvestorPlace
Elanco Animal Health's Q1 Earnings Show Improved Base Business, Analyst Highlights Slightly Delayed But Encouraging Pipeline
Elanco Animal Health (NYSE: ELAN) reports Q1 results: adjusted EPS $0.34 (-26% Y/Y), sales $1.21B (-4% Y/Y). 2024 guidance: EPS $0.88-$0.96, revenue $4.46-$4.52 billion. 
Via Benzinga
Elanco Animal Health (ELAN) Q1 2024 Earnings Call Transcript
ELAN earnings call for the period ending March 31, 2024. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Why Upstart Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Louisiana-Pacific Posts Upbeat Results, Joins Cricut, Elanco Animal, American Public Education And Other Big Stocks Moving Higher On Wednesday
Via Benzinga
ELAN Stock Earnings: Elanco Animal Health Beats EPS, Beats Revenue for Q1 2024
ELAN stock results show that Elanco Animal Health beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
Elanco Makes A Bullish Move On Its First Quarter Beat; Are Pet Health Stocks Forging A Comeback?
Elanco is the second animal health company to report better-than-expected first-quarter metrics. 
Via Investor's Business Daily
Investor Activism: Elanco Animal Health Settles with Ancora, Adds New Board Members
Elanco Animal Health settles with Ancora, expanding board to 14 members, including Ancora's nominees Craig Wallace and Kathy Turner. Ancora's significant stake in Elanco, approximately $250 million,... 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
B. Riley Financial's diverse suite of services goes beyond traditional financial service offerings. By leveraging cross-platform expertise and assets, B. Riley Financial companies are uniquely positioned to provide full service, collaborative solutions to our clients at every stage of the business life cycle and in all market conditions.

B. Riley refers to B. Riley Financial, Inc. and/or one or more of its subsidiaries or affiliates. Click here for further details.